Publications by authors named "Jakob Paur"

Claim this Profile
E
EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals.
Jan Willem van der Laan, Mikael Andersson, Sonja Beken, Milton Bonelli, Susanne Brendler-Schwaab, Jakob Paur

Br J Clin Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.
Jakob Paur, Maximilian Valler, Rebecca Sienel, Karin Taxauer, Klaus Holzmann

Liver Int· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy.
Nastasia Wilfinger, Shane Austin, Barbara Scheiber-Mojdehkar, Walter Berger, Siegfried Reipert, Jakob Paur

Oncotarget· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?
Jakob Paur, Lisa Nika, Christiane Maier, Alexander Moscu-Gregor, Julia Kostka

Hepatology· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?
Christine Heinzle, Zeynep Erdem, Jakob Paur, Bettina Grasl-Kraupp, Klaus Holzmann

Curr Pharm Des· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.
Christine Gauglhofer, Jakob Paur, Waltraud C Schrottmaier, Bettina Wingelhofer, Daniela Huber

Carcinogenesis· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis